A. Douros

First name
A.
Last name
Douros
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
Ayele, H. T., Douros, A., & Filion, K. B. (2022). 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.15317
Douros, A., Yin, H., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2017). Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes Care. http://doi.org/10.2337/dc17-0595
Douros, A., Dell'Aniello, S., H. Y. Yu, O., Filion, K. B., Azoulay, L., & Suissa, S. (2018). Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k2693
Douros, A., Abrahami, D., Yin, H., H. Y. Yu, O., Renoux, C., Hudson, M., & Azoulay, L. (2018). Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. Epidemiology. http://doi.org/10.1097/ede.0000000000000891
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., et al. (2018). Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k4880
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018). Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care. http://doi.org/10.2337/dc17-2280
Abrahami, D., Douros, A., Yin, H., H. Y. Yu, O., Renoux, C., Bitton, A., & Azoulay, L. (2018). Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k872
Abrahami, D., Douros, A., Yin, H., H. Y. Yu, O., & Azoulay, L. (2019). Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes. Diabetes Care. http://doi.org/10.2337/dc19-0849
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H., & Suissa, S. (2019). Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.14056